Cost-effectiveness of low-level laser therapy (LLLT) in head and neck cancer patients receiving concurrent chemoradiation

dc.contributor.authorAntunes, Heilton S
dc.contributor.authorSchluckebier, Luciene Fontes
dc.contributor.authorHerchenhorn, Daniel
dc.contributor.authorSmall, Isabele A.
dc.contributor.authorAraújo, Carlos M.M.
dc.contributor.authorViégas, Celia Maria Pais
dc.contributor.authorRampini, Mariana P.
dc.contributor.authorFerreira, Elza M.S.
dc.contributor.authorDias, Fernando L.
dc.contributor.authorTeich, Vanessa
dc.contributor.authorTeich, Nelson
dc.contributor.authorFerreira, Carlos G.
dc.date.accessioned2022-08-16T12:54:59Z
dc.date.available2022-08-16T12:54:59Z
dc.date.issued2016
dc.description.abstractBackground: Oral mucositis is a major event increasing treatment costs of head and neck squamous cell carcinoma (HNSCC) patients treated with chemoradiation (CRT). This study was designed to estimate the cost-effectiveness of low-level laser therapy (LLLT) to prevent oral mucositis in HNSCC patients receiving CRT. Methods: From June 2007 to December 2010, 94 patients with HNSCC of nasopharynx, oropharynx, and hypopharynx entered a prospective, randomized, double blind, placebo-controlled, phase III trial. CRT consisted of conventional radiotherapy (RT: 70.2 Gy, 1.8 Gy/d, 5 times/wk) + concurrent cisplatin (100 mg/m2 ) every 3 weeks. An InGaAlP (660 nm–100 mW–4 J/cm2 ) laser diode was used for LLLT. Results: From the perspective of Brazil’s public health care system (SUS), total costs were higher in Placebo Group (PG) than Laser Group (LG) for opioid use (LG = US$ 9.08, PG = US$ 44.28), gastrostomy feeding (LG = US$ 50.50, PG = US$ 129.86), and hospitalization (PG = US$ 77.03). In LG, the cost was higher for laser therapy only (US$ 1880.57). The total incremental cost associated with the use of LLLT was US$ 1689.00 per patient. The incremental cost-effectiveness ratio (ICER) was US$ 4961.37 per grade 3–4 OM case prevented compared to no treatment. Conclusions: Our results indicate that morbidity was lower in the Laser Group and that LLLT was more cost-effective than placebo up to a threshold of at least US$ 5000 per mucositis case prevented. Clinical trial information: NCT01439724.
dc.identifier.citationAntunes,HS, Schluckebier LF, Herchenhorn D, Small IA, Araújo CMM, Viégas CMP et al. Cost-effectiveness of low-level laser therapy (LLLT) in head and neck cancer patients receiving concurrent chemoradiation. Oral Oncol. 2016;52:85-90. Doi: 10.1016/j.oraloncology.2015.10.022.
dc.identifier.otherDOI: 10.1016/j.oraloncology.2015.10.022
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/90
dc.language.isoen
dc.publisherOral Oncology
dc.subjectCost-effectivenessen
dc.subjectLow-level laser therapyen
dc.subjectOral mucositisen
dc.subjectHead and neck canceren
dc.subjectRadiotherapyen
dc.subjectChemotherapyen
dc.subjectQuality of lifeen
dc.subject.meshTreatment Outcomeen
dc.subject.meshProspective Studiesen
dc.subject.meshMucositis / prevention & controlen
dc.subject.meshMucositis / economicsen
dc.subject.meshMiddle Ageden
dc.subject.meshMaleen
dc.subject.meshLow-Level Light Therapy / economicsen
dc.subject.meshHumansen
dc.subject.meshHead and Neck Neoplasms / therapyen
dc.subject.meshHead and Neck Neoplasms / economicsen
dc.subject.meshFemaleen
dc.subject.meshDouble-Blind Methoden
dc.subject.meshCost-Benefit Analysisen
dc.subject.meshChemoradiotherapy / economicsen
dc.subject.meshChemoradiotherapy / adverse effectsen
dc.subject.meshCarcinoma, Squamous Cell / therapyen
dc.subject.meshCarcinoma, Squamous Cell / economicsen
dc.subject.meshBrazilen
dc.subject.meshAgeden
dc.titleCost-effectiveness of low-level laser therapy (LLLT) in head and neck cancer patients receiving concurrent chemoradiation
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Antunes HS et al_2016.pdf
Tamanho:
427.75 KB
Formato:
Adobe Portable Document Format
Descrição:
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição: